Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07188779

Impact of RADA16 Use on Outcomes Following Tonsillectomy in Children

Status
Not Yet Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
134 (estimated)
Sponsor
Rutgers, The State University of New Jersey · Academic / Other
Sex
All
Age
3 Years – 17 Years
Healthy volunteers
Not accepted

Summary

The purpose of the research is to determine if RADA16 (also known as PuraStat®, PuraGel®, or PuraSinus®) improves patient outcomes following pediatric tonsillectomy procedures. Researchers will compare application of device RADA16 to application of no device to see if RADA16 works to treat post tonsillectomy hemorrhage.Participants will: Undergo tonsillectomy procedure. Receive and fill out a survey sent via email every 2 days following their procedure for 15 days, plus an additional survey on day 30, and track their symptoms.

Detailed description

This is a prospective study evaluating the impact of intraoperative RADA16 application on the postoperative course following pediatric tonsillectomy as it relates to pain, bleeding, readmission, and use of a rescue analgesic (ex., oxycodone). We propose a randomized controlled trial whereby patients undergoing tonsillectomy would either receive a standard analgesic regimen (postoperative acetaminophen and NSAIDs plus oxycodone as a supplemental analgesic) versus intraoperative RADA16 application plus a standard analgesic regimen.

Conditions

Interventions

TypeNameDescription
DEVICERADA16 hydrogelApplication of 2.5% RADA16 hydrogel to the tonsillar fossae following tonsillectomy using a sterile syringe tip applicator. The gel will be spread into a thin layer within the tonsillar fossae. The gel will be left to sit for 60 seconds. A suction device will then be used to remove any excess RADA16 hydrogel, leaving a thin layer of RADA16 over the tonsillar fossae.

Timeline

Start date
2026-04-01
Primary completion
2027-12-01
Completion
2027-12-01
First posted
2025-09-23
Last updated
2026-04-01

Regulatory

Source: ClinicalTrials.gov record NCT07188779. Inclusion in this directory is not an endorsement.